Targeting the PI3K/Akt pathway in prostate cancer: Challenges and opportunities (Review)Paul Toren, Amina Zoubeidi|International Journal of Oncology|2014Cited by 158
Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate CancerPaul Toren, Amina Zoubeidi|PLoS ONE|2016Cited by 36
Using ex vivo culture to assess dynamic phenotype changes in human prostate macrophages following exposure to therapeutic drugsClovis Boibessot, Paul Toren|Scientific Reports|2021Cited by 10
Pre-clinical targeting of enzalutamide-resistant prostate cancerPaul Toren|cIRcle (University of British Columbia)|2017Cited by 0